Inhibited metabolism of terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide, bepridil, ergot derivatives. Decreased voriconazole plasma conc. Decreased amprenavir conc. Decreased atazanavir exposure. Increased indinavir metabolism. Higher frequency of adverse clinical experiences & lab abnormalities w/ ritonavir. Developed rash w/ clarithromycin. Reduced plasma conc of HMG-CoA reductase inhibitors eg, atorvastatin, pravastatin or simvastatin, Ca-channel blockers eg, verapamil, felodepine, nifedipine, nicardipine. Reduced plasma conc by St. John's wort. Induced metabolism of sertraline. Monitor signs of w/drawal w/ methadone. False +ve urine cannabinoid test results. Concomitant use w/ fosamprenavir Ca, saquinavir, rifamycins, itraconazole, carbamazepine, OCs.
Sign Out
